Key points from article :
Arctic Therapeutics, an Icelandic biotech firm, secured €26.5 million in Series A funding to advance its pipeline of treatments for neurodegenerative and inflammatory diseases. The company's flagship drug, AT-001, is an oral therapy targeting amyloid-induced angiopathies, which contribute to rare hereditary dementias and Alzheimer’s disease.
The drug disrupts disulfide bonds that stabilize harmful protein aggregates, potentially preventing and reversing neurodegenerative damage. A Phase 2a study in Iceland showed promising results, reducing stroke risks and slowing dementia progression in patients with a specific mutation. This led to the approval of a Phase 2b/3 trial by the European Medicines Agency, focused on Hereditary Cystatin C Amyloid Angiopathy (HCCAA). Arctic’s broader goal is to apply AT-001 to Alzheimer’s by preventing and dissolving amyloid plaques and tau tangles.
Founded in 2015 as a spin-off from the Children’s Hospital of Philadelphia, Arctic combines genomics research with AI in Iceland. The company’s additional candidate, AT-004, targets inflammatory skin conditions like acne, with a Phase 2a trial planned in Europe. Investors in the Series A round include the EIC Fund, Kaldbakur, and Cerebrum DAO. The funding supports Arctic’s mission to address global healthcare challenges, particularly in dementia and age-related conditions.
